Novo Nordisk A/S (NYSE:NVO)

52.27
Delayed Data
As of Aug 23
 -0.43 / -0.82%
Today’s Change
41.23
Today|||52-Week Range
52.84
+13.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$93.3B

Company Description

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Bagsværd Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-9085

Employees

Shareholders

Other institutional7.31%
Mutual fund holders2.09%
Individual stakeholders--

Top Executives

Lars Fruergaard JørgensenPresident & Chief Executive Officer
Maziar Mike DoustdarExecutive Vice President-International Operations
Karsten Munk KnudsenChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Alan C. MosesSenior Vice President & Chief Medical Officer